ArticleWorld journal of urology2026
Correlation between intravesical prostatic protrusion and ejaculatory dysfunction after tamsulosin treatment in men with BPH.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the correlation between prostate morphological measurements and changes in ejaculatory function during short-term tamsulosin therapy in men with benign prostatic hyperplasia (BPH).
methodsThis prospective study included 214 sexually active men with moderate-to-severe lower urinary tract symptoms (LUTS) who received tamsulosin 0.4 mg/day for eight weeks. Patients with prior treatment for BPH or pre-existing sexual dysfunction were excluded. Symptom severity and ejaculatory function were evaluated using the International Prostate Symptom Score (IPSS) and the Male Sexual Health Questionnaire–Ejaculatory Dysfunction Short Form (MSHQ-EjD-SF). Prostate morphological measurements, including overall dimensions and intravesical prostatic protrusion (IPP), were obtained by transabdominal ultrasonography. Correlations between changes in MSHQ-EjD scores (ΔMSHQ-EjD) and clinical or anatomical variables were assessed using Spearman’s rank coefficients.
resultsAfter eight weeks of treatment, the median IPSS significantly decreased from 18 to 14 (p < 0.001) and Qmax increased from 9.2 to 14.0 mL/s (p < 0.001). The median MSHQ-EjD-SF score declined from 11 to 7 (p < 0.001), while higher ejaculatory bother scores were observed after treatment. ΔMSHQ-EjD was negatively correlated with IPP (ρ = −0.386), prostate length (ρ = −0.250), and age (ρ = −0.334) (all p < 0.01). Patients with IPP > 10 mm showed a less pronounced decline in ejaculatory function compared with lower IPP grades (p < 0.001).
conclusionsTamsulosin improved urinary symptoms but was associated with a decline in ejaculatory function. Prostate morphological characteristics, particularly IPP > 10 mm and longer prostate length, were associated with a less pronounced decline in ejaculatory function. Although these correlations were modest, the findings may help contextualize the relationship between prostate anatomy and tamsulosin-related ejaculatory changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.